Maintenance Notice: You may encounter a brief disruption lasting 1-2 minutes at any time between 11:00 PM GMT on 21 July 2026 and 4:00 AM GMT on 22 July 2026.

This PLSP provides a short summary of an original scientific article that presented results from the PRIMA study after 3.5 years of follow-up time. The original article was published in the European Journal of Cancer in 2023. The PRIMA study included adult patients with newly diagnosed advanced high-risk ovarian cancer whose tumors shrunk or became undetectable after treatment with chemotherapy with or without surgery. The PRIMA study evaluated how well the drug niraparib, also known as Zejula, worked at delaying or preventing ovarian cancer from coming back (recurring) or getting worse (progressing) compared with placebo (a substance with no effects that a doctor gives to a patient instead of a drug). The first results from the PRIMA study were published in 2019, when patients had participated in the PRIMA study for about 1.2 years.The article this PLSP is based on reports longer-term data from the PRIMA study, when patients had participated in the PRIMA study for about 3.5 years. Patients were monitored (or followed) for a longer time to understand how well niraparib continued to work and to evaluate whether the safety of niraparib changed with additional time being monitoredThis Plain Language Summary of Publication article (PLSP) from Future Oncology looks at the longer-term results (3.5 years follow-up) of the PRIMA study. The PRIMA study evaluated how well the drug niraparib worked in participants with newly diagnosed advanced high-risk ovarian cancer whose tumors shrunk or became undetectable after treatment with chemotherapy with or without surgery.

Visit the site using the link to read the article.

This PLSP is based on an article called ‘Progression-free survival and safety at 3.5 years of follow-up: results from the randomised phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer’ and was published in the European Journal of Cancer.

Visit the European Journal of Cancer site using the link to read the article.